Download PDF
Semin intervent Radiol 2017; 34(02): 092-100
DOI: 10.1055/s-0037-1602591
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Decision Making: Intra-arterial Therapies for Cholangiocarcinoma—TACE and TARE

Brian M. Currie
1   Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
,
Michael C. Soulen
1   Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
› Author Affiliations
Further Information

Publication History

Publication Date:
01 June 2017 (online)

Also available at
   Permissions and Reprints

Abstract

The incidence of intrahepatic cholangiocarcinoma (ICC) has been increasing in recent years and now represents the second most common primary hepatic cancer in the United States. The prognosis is dismal without surgical resection. In patients ineligible to receive curative treatments, locoregional therapies represent a diverse array of techniques that can stabilize or reverse tumor progression to improve overall survival and reduce tumor-related symptoms. Transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) have been demonstrated to be efficacious methods for this patient population. Deciding between these two options is challenging. This article reviews the differences in patient selection, preprocedural evaluation, financial considerations and availability, quality of life, and rates of complications and overall survival.

Keywords

intrahepatic cholangiocarcinoma - locoregional therapy - transarterial chemoembolization - transarterial radioembolization - interventional radiology
 

  • References

  • 1 Hong K, Geschwind JF. Locoregional intra-arterial therapies for unresectable intrahepatic cholangiocarcinoma. Semin Oncol 2010; 37 (02) 110-117
    CrossrefPubMedSearch in Google Scholar
  • 2 Weber SM, Jarnagin WR, Klimstra D, DeMatteo RP, Fong Y, Blumgart LH. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg 2001; 193 (04) 384-391
    CrossrefPubMedSearch in Google Scholar
  • 3 Tan JC, Coburn NG, Baxter NN, Kiss A, Law CH. Surgical management of intrahepatic cholangiocarcinoma--a population-based study. Ann Surg Oncol 2008; 15 (02) 600-608
    CrossrefPubMedSearch in Google Scholar
  • 4 Park J, Kim MH, Kim KP. , et al. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver 2009; 3 (04) 298-305
    CrossrefPubMedSearch in Google Scholar
  • 5 Endo I, Gonen M, Yopp AC. , et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008; 248 (01) 84-96
    CrossrefPubMedSearch in Google Scholar
  • 6 Zen Y, Adsay NV, Bardadin K. , et al. Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Mod Pathol 2007; 20 (06) 701-709
    CrossrefPubMedSearch in Google Scholar
  • 7 Maithel SK, Gamblin TC, Kamel I, Corona-Villalobos CP, Thomas M, Pawlik TM. Multidisciplinary approaches to intrahepatic cholangiocarcinoma. Cancer 2013; 119 (22) 3929-3942
    CrossrefPubMedSearch in Google Scholar
  • 8 Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg 2003; 10 (04) 288-291
    CrossrefPubMedSearch in Google Scholar
  • 9 Yang J, Yan LN. Current status of intrahepatic cholangiocarcinoma. World J Gastroenterol 2008; 14 (41) 6289-6297
    CrossrefPubMedSearch in Google Scholar
  • 10 Isaji S, Kawarada Y, Taoka H, Tabata M, Suzuki H, Yokoi H. Clinicopathological features and outcome of hepatic resection for intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg 1999; 6 (02) 108-116
    CrossrefPubMedSearch in Google Scholar
  • 11 Chung YE, Kim MJ, Park YN. , et al. Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. Radiographics 2009; 29 (03) 683-700
    CrossrefPubMedSearch in Google Scholar
  • 12 Kim Y-J, Yun M, Lee WJ, Kim KS, Lee JD. Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging 2003; 30 (11) 1467-1472
    CrossrefPubMedSearch in Google Scholar
  • 13 Grobmyer SR, Wang L, Gonen M. , et al. Perihepatic lymph node assessment in patients undergoing partial hepatectomy for malignancy. Ann Surg 2006; 244 (02) 260-264
    CrossrefPubMedSearch in Google Scholar
  • 14 Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet 2014; 383 (9935): 2168-2179
    CrossrefPubMedSearch in Google Scholar
  • 15 Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 2008; 10 (02) 77-82
    CrossrefPubMedSearch in Google Scholar
  • 16 Welzel TM, Graubard BI, El-Serag HB. , et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 2007; 5 (10) 1221-1228
    CrossrefPubMedSearch in Google Scholar
  • 17 McGlynn KA, Tarone RE, El-Serag HB. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev 2006; 15 (06) 1198-1203
    CrossrefPubMedSearch in Google Scholar
  • 18 Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 2006; 25 (27) 3818-3822
    CrossrefPubMedSearch in Google Scholar
  • 19 Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?. J Hepatol 2004; 40 (03) 472-477
    CrossrefPubMedSearch in Google Scholar
  • 20 de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med 1999; 341 (18) 1368-1378
    CrossrefPubMedSearch in Google Scholar
  • 21 Surveillance, Epidemiology, and End Results (SEER) Program Populations (1969-2014). National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released March 2016. Available at: www.seer.cancer.gov/popdata . Accessed April 12, 2017
    PubMed
  • 22 Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33 (06) 1353-1357
    CrossrefPubMedSearch in Google Scholar
  • 23 Welzel TM, McGlynn KA, Hsing AW, O'Brien TR, Pfeiffer RM. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 2006; 98 (12) 873-875
    CrossrefPubMedSearch in Google Scholar
  • 24 Poultsides GA, Zhu AX, Choti MA, Pawlik TM. Intrahepatic cholangiocarcinoma. Surg Clin North Am 2010; 90 (04) 817-837
    CrossrefPubMedSearch in Google Scholar
  • 25 Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000; 95 (01) 204-207
    CrossrefPubMedSearch in Google Scholar
  • 26 Kiefer MV, Albert M, McNally M. , et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, Ethiodol, and polyvinyl alcohol: a 2-center study. Cancer 2011; 117 (07) 1498-1505
    CrossrefPubMedSearch in Google Scholar
  • 27 Farges O, Fuks D, Le Treut Y-P. , et al. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: by the AFC-IHCC-2009 study group. Cancer 2011; 117 (10) 2170-2177
    CrossrefPubMedSearch in Google Scholar
  • 28 Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg 2014; 149 (06) 565-574
    CrossrefPubMedSearch in Google Scholar
  • 29 National Comprehensive Cancer Network. Hepatobiliary Cancers (Version 2.2016). Available at: https://www.nccn.org/professionals/physician_gls/PDF/hepatobiliary.pdf . Accessed August 31, 2016
    PubMed
  • 30 Ohtsuka M, Ito H, Kimura F. , et al. Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg 2002; 89 (12) 1525-1531
    CrossrefPubMedSearch in Google Scholar
  • 31 Pichlmayr R, Lamesch P, Weimann A, Tusch G, Ringe B. Surgical treatment of cholangiocellular carcinoma. World J Surg 1995; 19 (01) 83-88
    CrossrefPubMedSearch in Google Scholar
  • 32 Simo KA, Halpin LE, McBrier NM. , et al. Multimodality treatment of intrahepatic cholangiocarcinoma: a review. J Surg Oncol 2016; 113 (01) 62-83
    CrossrefPubMedSearch in Google Scholar
  • 33 Nathan H, Pawlik TM, Wolfgang CL, Choti MA, Cameron JL, Schulick RD. Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis. J Gastrointest Surg 2007; 11 (11) 1488-1496 , discussion 1496–1497
    CrossrefPubMedSearch in Google Scholar
  • 34 Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 2000; 69 (08) 1633-1637
    PubMedSearch in Google Scholar
  • 35 Shimoda M, Farmer DG, Colquhoun SD. , et al. Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature. Liver Transpl 2001; 7 (12) 1023-1033
    CrossrefPubMedSearch in Google Scholar
  • 36 Fu B-S, Zhang T, Li H. , et al. The role of liver transplantation for intrahepatic cholangiocarcinoma: a single-center experience. Eur Surg Res 2011; 47 (04) 218-221
    CrossrefPubMedSearch in Google Scholar
  • 37 De Vreede I, Steers JL, Burch PA. , et al. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl 2000; 6 (03) 309-316
    CrossrefPubMedSearch in Google Scholar
  • 38 Shinohara ET, Mitra N, Guo M, Metz JM. Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2008; 72 (05) 1495-1501
    CrossrefPubMedSearch in Google Scholar
  • 39 Dawson LA, McGinn CJ, Normolle D. , et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000; 18 (11) 2210-2218
    CrossrefPubMedSearch in Google Scholar
  • 40 Jirtle RL, Anscher MS, Alati T. Radiation sensitivity of the liver. In: Altman KI, Lett JT. , ed. Advances in Radiation Biology: Relative Radiation Sensitivities of Human Organ Systems, Part IV. Vol 14. San Diego, CA: Academic Press; 1990: 269-311
    Search in Google Scholar
  • 41 Tao R, Krishnan S, Bhosale PR. , et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis. J Clin Oncol 2016; 34 (03) 219-226
    CrossrefPubMedSearch in Google Scholar
  • 42 Valle JW, Furuse J, Jitlal M. , et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol 2014; 25 (02) 391-398
    CrossrefPubMedSearch in Google Scholar
  • 43 Valle J, Wasan H, Palmer DH. , et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362 (14) 1273-1281
    CrossrefPubMedSearch in Google Scholar
  • 44 Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007; 96 (06) 896-902
    CrossrefPubMedSearch in Google Scholar
  • 45 Okusaka T, Nakachi K, Fukutomi A. , et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010; 103 (04) 469-474
    CrossrefPubMedSearch in Google Scholar
  • 46 Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37 (02) 429-442
    CrossrefPubMedSearch in Google Scholar
  • 47 Chua TC, Liauw W, Saxena A. , et al. Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. Liver Int 2010; 30 (02) 166-174
    CrossrefPubMedSearch in Google Scholar
  • 48 Rayar M, Sulpice L, Edeline J. , et al. Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment. Ann Surg Oncol 2015; 22 (09) 3102-3108
    CrossrefPubMedSearch in Google Scholar
  • 49 Seidensticker R, Ricke J, Seidensticker M. Integration of chemoembolization and radioembolization into multimodal treatment of cholangiocarcinoma. Best Pract Res Clin Gastroenterol 2015; 29 (02) 319-332
    PubMedSearch in Google Scholar
  • 50 Seidensticker R, Seidensticker M, Doegen K. , et al. Extensive use of interventional therapies improves survival in unresectable or recurrent intrahepatic cholangiocarcinoma. Gastroenterol Res Pract 2016; 2016: 8732521
    CrossrefPubMedSearch in Google Scholar
  • 51 Fu Y, Yang W, Wu W, Yan K, Xing BC, Chen MH. Radiofrequency ablation in the management of unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 2012; 23 (05) 642-649
    CrossrefPubMedSearch in Google Scholar
  • 52 Zhang S-J, Hu P, Wang N. , et al. Thermal ablation versus repeated hepatic resection for recurrent intrahepatic cholangiocarcinoma. Ann Surg Oncol 2013; 20 (11) 3596-3602
    CrossrefPubMedSearch in Google Scholar
  • 53 Xu HX, Wang Y, Lu MD, Liu LN. Percutaneous ultrasound-guided thermal ablation for intrahepatic cholangiocarcinoma. Br J Radiol 2012; 85 (1016): 1078-1084
    CrossrefPubMedSearch in Google Scholar
  • 54 Lo CM, Ngan H, Tso WK. , et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35 (05) 1164-1171
    CrossrefPubMedSearch in Google Scholar
  • 55 Llovet JM, Real MI, Montaña X. , et al; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359 (9319): 1734-1739
    CrossrefPubMedSearch in Google Scholar
  • 56 Marelli L, Stigliano R, Triantos C. , et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30 (01) 6-25
    CrossrefPubMedSearch in Google Scholar
  • 57 Gupta S, Johnson MM, Murthy R. , et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005; 104 (08) 1590-1602
    CrossrefPubMedSearch in Google Scholar
  • 58 Salem R, Lewandowski RJ, Kulik L. , et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011; 140 (02) 497-507.e2
    CrossrefPubMedSearch in Google Scholar
  • 59 Salem R, Lewandowski RJ, Mulcahy MF. , et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138 (01) 52-64
    CrossrefPubMedSearch in Google Scholar
  • 60 Kennedy A, Coldwell D, Sangro B, Wasan H, Salem R. Integrating radioembolization into the treatment paradigm for metastatic neuroendocrine tumors in the liver. Am J Clin Oncol 2012; 35 (04) 393-398
    CrossrefPubMedSearch in Google Scholar
  • 61 Kennedy AS, Dezarn WA, McNeillie P. , et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008; 31 (03) 271-279
    CrossrefPubMedSearch in Google Scholar
  • 62 Ando E, Tanaka M, Yamashita F. , et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95 (03) 588-595
    CrossrefPubMedSearch in Google Scholar
  • 63 Barber FD, Mavligit G, Kurzrock R. Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview. Cancer Treat Rev 2004; 30 (05) 425-436
    CrossrefPubMedSearch in Google Scholar
  • 64 Vogl TJ, Zangos S, Eichler K, Yakoub D, Nabil M. Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update. Eur Radiol 2007; 17 (04) 1025-1034
    CrossrefPubMedSearch in Google Scholar
  • 65 Kirchhoff T, Zender L, Merkesdal S. , et al. Initial experience from a combination of systemic and regional chemotherapy in the treatment of patients with nonresectable cholangiocellular carcinoma in the liver. World J Gastroenterol 2005; 11 (08) 1091-1095
    CrossrefPubMedSearch in Google Scholar
  • 66 Aliberti C, Benea G, Tilli M, Fiorentini G. Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results. Cardiovasc Intervent Radiol 2008; 31 (05) 883-888
    CrossrefPubMedSearch in Google Scholar
  • 67 Vogl TJ, Naguib NN, Nour-Eldin EA. , et al. Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: results and prognostic factors governing treatment success. Int J Cancer 2012; 131 (03) 733-740
    CrossrefPubMedSearch in Google Scholar
  • 68 Park SY, Kim JH, Yoon HJ, Lee IS, Yoon HK, Kim KP. Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. Clin Radiol 2011; 66 (04) 322-328
    CrossrefPubMedSearch in Google Scholar
  • 69 Herber S, Otto G, Schneider J. , et al. Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 2007; 30 (06) 1156-1165
    CrossrefPubMedSearch in Google Scholar
  • 70 Poggi G, Amatu A, Montagna B. , et al. OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 2009; 32 (06) 1187-1192
    CrossrefPubMedSearch in Google Scholar
  • 71 Burger I, Hong K, Schulick R. , et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 2005; 16 (03) 353-361
    CrossrefPubMedSearch in Google Scholar
  • 72 Scheuermann U, Kaths JM, Heise M. , et al. Comparison of resection and transarterial chemoembolisation in the treatment of advanced intrahepatic cholangiocarcinoma--a single-center experience. Eur J Surg Oncol 2013; 39 (06) 593-600
    CrossrefPubMedSearch in Google Scholar
  • 73 Gusani NJ, Balaa FK, Steel JL. , et al. Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. J Gastrointest Surg 2008; 12 (01) 129-137
    CrossrefPubMedSearch in Google Scholar
  • 74 Ibrahim SM, Mulcahy MF, Lewandowski RJ. , et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer 2008; 113 (08) 2119-2128
    CrossrefPubMedSearch in Google Scholar
  • 75 Hoffmann RT, Paprottka PM, Schön A. , et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol 2012; 35 (01) 105-116
    CrossrefPubMedSearch in Google Scholar
  • 76 Saxena A, Bester L, Chua TC, Chu FC, Morris DL. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol 2010; 17 (02) 484-491
    CrossrefPubMedSearch in Google Scholar
  • 77 Mouli S, Memon K, Baker T. , et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol 2013; 24 (08) 1227-1234
    CrossrefPubMedSearch in Google Scholar
  • 78 Hyder O, Marsh JW, Salem R. , et al. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol 2013; 20 (12) 3779-3786
    CrossrefPubMedSearch in Google Scholar
  • 79 Kuhlmann JB, Euringer W, Spangenberg HC. , et al. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol 2012; 24 (04) 437-443
    CrossrefPubMedSearch in Google Scholar
  • 80 Ray Jr CEJ, Edwards A, Smith MT. , et al. Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 2013; 24 (08) 1218-1226
    CrossrefPubMedSearch in Google Scholar
  • 81 Kennedy A, Nag S, Salem R. , et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007; 68 (01) 13-23
    CrossrefPubMedSearch in Google Scholar
  • 82 Kulik LM, Atassi B, van Holsbeeck L. , et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006; 94 (07) 572-586
    CrossrefPubMedSearch in Google Scholar
  • 83 Yang L, Shan J, Shan L, Saxena A, Bester L, Morris DL. Trans-arterial embolisation therapies for unresectable intrahepatic cholangiocarcinoma: a systematic review. J Gastrointest Oncol 2015; 6 (05) 570-588
    PubMedSearch in Google Scholar
  • 84 Rafi S, Piduru SM, El-Rayes B. , et al. Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc Intervent Radiol 2013; 36 (02) 440-448
    CrossrefPubMedSearch in Google Scholar
  • 85 Al-Adra DP, Gill RS, Axford SJ, Shi X, Kneteman N, Liau SS. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol 2015; 41 (01) 120-127
    CrossrefPubMedSearch in Google Scholar
  • 86 Boehm LM, Jayakrishnan TT, Miura JT. , et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol 2015; 111 (02) 213-220
    CrossrefPubMedSearch in Google Scholar
  • 87 Kloeckner R, Ruckes C, Kronfeld K. , et al. Selective internal radiotherapy (SIRT) versus transarterial chemoembolization (TACE) for the treatment of intrahepatic cholangiocellular carcinoma (CCC): study protocol for a randomized controlled trial. Trials 2014; 15: 311
    CrossrefPubMedSearch in Google Scholar
  • 88 Kim W, Clark TW, Baum RA, Soulen MC. Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol 2001; 12 (08) 965-968
    CrossrefPubMedSearch in Google Scholar
  • 89 Guan Y-S, He Q, Wang M-Q. Transcatheter arterial chemoembolization: history for more than 30 years. ISRN Gastroenterol 2012; 2012: 480650
    PubMedSearch in Google Scholar
  • 90 Rostambeigi N, Dekarske AS, Austin EE, Golzarian J, Cressman EN. Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Vasc Interv Radiol 2014; 25 (07) 1075-1084
    CrossrefPubMedSearch in Google Scholar